Cytori Therapeutics (CYTX) Reaches New 12-Month Low at $0.27
Cytori Therapeutics Inc (NASDAQ:CYTX) hit a new 52-week low on Wednesday . The stock traded as low as $0.27 and last traded at $0.28, with a volume of 1465300 shares changing hands. The stock had previously closed at $0.30.
Several equities research analysts recently weighed in on the stock. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.
Cytori Therapeutics (NASDAQ:CYTX) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The business had revenue of $1.77 million during the quarter, compared to the consensus estimate of $2.04 million. During the same quarter in the previous year, the firm posted ($0.26) EPS. research analysts expect that Cytori Therapeutics Inc will post -0.62 earnings per share for the current year.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Stock Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related stocks with our FREE daily email newsletter.